Volume | 3,978,538 |
|
|||||
News | - | ||||||
Day High | 0.8299 | Low High |
|||||
Day Low | 0.74 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Seres Therapeutics Inc | MCRB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.7409 | 0.74 | 0.8299 | 0.825 | 0.7427 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10,342 | 3,978,538 | US$ 0.787244 | US$ 3,132,080 | - | 0.54 - 6.65 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:57:15 | formt | 100 | US$ 0.8369 | USD |
Seres Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
123.83M | 151.01M | - | 126.33M | -113.72M | -0.75 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Seres Therapeutics News
Date | Time | Source | News Article |
---|---|---|---|
4/09/2024 | 06:00 | Business Wire | Seres Therapeutics Announces Completion of Patient.. |
3/28/2024 | 06:00 | Business Wire | Seres Therapeutics Reports Inducement Grants Under Nasdaq.. |
3/19/2024 | 06:00 | Business Wire | Seres Therapeutics Reports Inducement Grants Under Nasdaq.. |
3/05/2024 | 09:18 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
3/05/2024 | 09:13 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee.. |
3/05/2024 | 06:05 | Edgar (US Regulatory) | Form 8-K - Current report |
3/05/2024 | 06:00 | Business Wire | Seres Therapeutics Reports Fourth Quarter and Full Year 2023.. |
3/05/2024 | 05:05 | IH Market News | U.S. Futures Dip, Crude Oil Fluctuates |
2/28/2024 | 06:00 | Business Wire | Seres Therapeutics to Host Fourth Quarter 2023 Financial.. |
2/27/2024 | 06:00 | Business Wire | Seres Therapeutics to Participate in Cowen 44th Annual.. |
2/26/2024 | 06:06 | Edgar (US Regulatory) | Form 8-K - Current report |
2/26/2024 | 06:00 | Business Wire | Seres Therapeutics Announces the Appointment of Marella.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MCRB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.58 | 0.8299 | 0.54 | 0.7064414 | 5,810,375 | 0.2569 | 44.29% |
1 Month | 0.78 | 0.8299 | 0.54 | 0.6954072 | 4,628,095 | 0.0569 | 7.29% |
3 Months | 1.13 | 1.24 | 0.54 | 0.8706753 | 4,141,342 | -0.2931 | -25.94% |
6 Months | 1.39 | 2.05 | 0.54 | 1.07 | 4,676,598 | -0.5531 | -39.79% |
1 Year | 6.22 | 6.65 | 0.54 | 2.25 | 3,775,433 | -5.38 | -86.55% |
3 Years | 20.65 | 25.055 | 0.54 | 4.47 | 2,094,807 | -19.81 | -95.95% |
5 Years | 7.01 | 38.50 | 0.54 | 7.43 | 1,590,342 | -6.17 | -88.06% |
Seres Therapeutics Description
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401. |